

Financial news for ENTA dated on 2020-05-06: Enanta Pharmaceuticals Q2 EPS \$(0.300) May Not Compare To \$(0.870) Estimate, Sales \$27.600M Miss \$27.640M Estimate

Financial news for ENTA dated on 2020-03-17: Baird Upgrades Enanta Pharmaceuticals to Outperform, Announces \$60 Price Target

Financial news for ENTA dated on 2020-03-13: Enanta Pharma Reports Will 'Leverage Proven Antiviral and Respiratory Expertise to Evaluate Existing Compounds and New Approaches for Treating the Coronavirus'

Financial news for ENTA dated on 2020-02-06: Enanta Pharmaceuticals Q1 EPS \$0.65 Beats \$0.58 Estimate, Sales \$52.6M Miss \$58.86M Estimate

Financial news for ENTA dated on 2019-11-22: JMP Securities Downgrades Enanta Pharmaceuticals to Market Perform

Financial news for ENTA dated on 2019-11-21: Enanta Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 EPS and sales results.

Financial news for ENTA dated on 2019-11-21: Enanta Pharmaceuticals Q4 EPS \$0.44 Misses \$0.53 Estimate, Sales \$51.313M Miss \$55.94M Estimate

Financial news for ENTA dated on 2019-11-11: Enanta Pharmaceuticals Announces 3 Poster Presentations at The Liver Meeting 2019

Financial news for ENTA dated on 2019-10-03: Enanta Pharma Highlights New Data From Co.'s Phase 2a Human Challenge Study Of EDP-938 For RSV Showed Highly Statistically Significant Reductions in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay

Financial news for ENTA dated on 2019-09-26: Enanta Pharmaceuticals shares are trading lower after JP Morgan downgraded the company from Neutral to Underweight and lowered the price target from \$86 to \$57.

Financial news for ENTA dated on 2019-09-26: JP Morgan Downgrades Enanta Pharmaceuticals to Underweight, Lowers Price Target to \$57

Financial news for ENTA dated on 2019-09-25: Enanta Announces ARGON-1 Study Of FXR Agonist, EDP-305, For The Treatment Of NASH Met Primary And Key Secondary Endpoint

Financial news for ENTA dated on 2019-08-06: Enanta Pharmaceuticals Q3 EPS \$0.33 Beats \$0.16 Estimate, Sales \$44.4M Miss \$46.98M Estimate

Financial news for ENTA dated on 2019-08-02: Enanta's HCV Collaboration Partner AbbVie Receives Approval By European Commission For MAVIRET To Shorten Treatment Duration To Eight Weeks For Treatment-Naive HCV Patients With Compensated Cirrhosis

Financial news for ENTA dated on 2019-07-08: Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-514, its Lead Core Inhibitor for the Treatment of Hepatitis B Virus

Financial news for ENTA dated on 2019-05-07: Enanta Pharmaceuticals Q2 EPS \$0.2 Beats \$(0.06) Estimate, Sales \$39.631M Miss \$40.88M Estimate

Financial news for ENTA dated on 2019-04-11: Enanta Pharma To Present Preclinical Data From Hep B, NASH Programs At Int'l. Liver Congress

Financial news for ENTA dated on 2019-03-20: Enanta Pharma shares are trading lower after the company announced a 1.6M share common stock offering at \$97 per share.

Financial news for ENTA dated on 2019-03-18: Enanta Pharmaceuticals Completes Enrollment In Two Ongoing Phase 2 Studies

Financial news for ENTA dated on 2019-02-06: Enanta Pharmaceuticals Q1 EPS \$1.25 Misses \$1.47 Estimate, Sales \$69.886M Miss \$73.02M Estimate

Financial news for ENTA dated on 2019-01-03: Enanta Pharma Will Offer Updates On R&D Programs, Business Outlook At JP Morgan Healthcare Conf. On Jan. 7

Financial news for ENTA dated on 2018-12-13: Berenberg Initiates Coverage On Enanta Pharmaceuticals with Buy Rating, Announces \$80 Price Target

Financial news for ENTA dated on 2018-11-26: Enanta Pharma Q4 EPS \$1.30 Beats \$1.19 Estimate, Sales \$67.205M Miss \$68.52M Estimate

Financial news for ENTA dated on 2018-10-23: Enanta Pharma Reports Phase 1 Results, Initiation Of Phase 2a Study Of EDP-938 For Respiratory Syncytial Virus

Financial news for ENTA dated on 2018-08-08: Oppenheimer Downgrades Enanta Pharmaceuticals to Perform

Financial news for ENTA dated on 2018-08-07: Enanta Pharmaceuticals Q3 EPS \$0.97 Misses \$0.98 Estimate, Sales \$57.3M Beat \$56.93M Estimate

Financial news for ENTA dated on 2018-06-06: Roth Capital Initiates Coverage On Enanta Pharmaceuticals with Buy Rating, Announces \$133 Price Target

Financial news for ENTA dated on 2018-05-24: Oppenheimer Initiates Coverage On Enanta Pharmaceuticals with Outperform Rating, Announces \$135 Price Target

Financial news for ENTA dated on 2018-02-21: RBC Capital Global Healthcare Conference Begins Today, Presenters Include: Chemed, Revance, Eagle Pharma, Enanta, Gilead, TransEnterix, Immunogen, and Incyte

Financial news for ENTA dated on 2018-02-14: Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma

Financial news for ENTA dated on 2018-02-08: JP Morgan Downgrades Enanta Pharmaceuticals to Neutral

Financial news for ENTA dated on 2018-02-07: Enanta Pharma Reports Q1 EPS \$0.59 vs \$(0.26) In Same Qtr. Last Year, Sales \$38.1M vs \$31M Est.

Financial news for ENTA dated on 2018-01-05: Enanta Pharma Offers Update On R&D Programs

Financial news for ENTA dated on 2018-01-02: RBC Capital Downgrades Enanta Pharmaceuticals to Sector Perform

Financial news for ENTA dated on 2017-11-30: Enanta Says AbbVie's MAVIRET Is Now Available In Japan For Treatment Of GT1-6

Financial news for ENTA dated on 2017-11-20: Enanta Pharmaceuticals Reports Q4 EPS \$1.86 vs \$2.13 Est., Sales \$75.9M vs \$73.12M Est.

Financial news for ENTA dated on 2017-10-23: Enanta Pharmaceuticals Announces 'Positive' Phase 1 a/b Clinical Results for its Lead FXR Agonist, EDP-305

Financial news for ENTA dated on 2017-09-27: Enanta Pharma Says AbbVie's MAVIRET Received Approval in Japan for Treatment of Chronic Hepatitis C

Financial news for ENTA dated on 2017-09-25: Cantor Fitzgerald Global Healthcare Conference Begins Today, Presenters Include: Verastem, Advaxis, Exelixis, Heron Therapeutics, and Enanta Pharma

Financial news for ENTA dated on 2017-09-15: RBC Initiated Coverage On 33 Pharma/Biotech Cos.

Financial news for ENTA dated on 2017-09-06: Baird Global Healthcare Conference Begins Today, Presenters Include: Tenet Healthcare, Mednax, Patterson Companies, Celgene, PerkinElmer, Premier, Acadia Healthcare, Envision Healthcare, and Enanta Pharmaceuticals

Financial news for ENTA dated on 2017-08-07: Enanta Pharmaceuticals Q3 EPS \$(0.44) vs \$(0.48) Est., Sales \$7.5M vs \$8.14M Est.

Financial news for ENTA dated on 2017-08-03: Adam Feuerstein Tweets: \$GILD competition. And \$ENTA gets a piece of Mavyret.

Financial news for ENTA dated on 2017-07-28: Enanta To Receive \$25M Milestone Payment From AbbVie Following EU Marketing Authorization For MAVIRET

Financial news for ENTA dated on 2017-07-11: JMP Securities Upgrades Enanta Pharmaceuticals to Market Outperform

Financial news for ENTA dated on 2017-06-26: Enanta Gives Update on EDP-938

Financial news for ENTA dated on 2017-05-08: Enanta Pharma Reports Q2 EPS \$(0.28) vs \$(0.38) Est., Sales \$9M vs \$9.19M Est.

Financial news for ENTA dated on 2017-04-21: Enanta Pharma Reports 8 Weeks of AbbVie's G/P Achieved High SVR Rates in Challenging-to-Treat Genotype 3 Chronic HCV Patients

Financial news for ENTA dated on 2017-04-20: AbbVie Says 'new data demonstrated high

SVR(12) rates across compensated cirrhotic patients with genotype 1, 2, 4, 5 or 6 chronic HCV infection with 12 weeks of treatment'

Financial news for ENTA dated on 2017-04-03: H.C. Wainwright Holding NASH Investor Conference Today; Attendees Include Allergan, Enanta Pharma, Madrigal Pharma, Vascular Biogenics, Albireo Pharma, CymaBay, Gemphire Therapeutics, And Galectin Therapeutics

Financial news for ENTA dated on 2017-02-27: Enanta Announces Positive Opinion for AbbVie's VIEKIRAX

Financial news for ENTA dated on 2017-02-08: Enanta Pharmaceuticals Reports Q1 EPS \$(0.26) vs \$(0.18) Est, Revenue \$10.4M vs \$11.94M Est

Financial news for ENTA dated on 2017-01-11: JP Morgan Healthcare Conf. Continues Today; Presenters Include Novocure, Zoetis, Oxford Immunotec, Enanta, Irhythm Tech, Walgreen's, & Mylan

Financial news for ENTA dated on 2017-01-04: FDA Grants Fast Track Designation to Enanta's FXR Agonist Candidate EDP-305 For NASH

Financial news for ENTA dated on 2016-04-28: JMP Securities Downgrades Enanta Pharmaceuticals to Market Perform

Financial news for ENTA dated on 2015-11-15: Enanta Announces New Data on VIEKIRA PAK in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis

Financial news for ENTA dated on 2015-10-23: Barclays Downgrades Enanta Pharmaceuticals to Underweight, Lowers PT to \$16.00

Financial news for ENTA dated on 2015-09-28: AbbVie's VIEKIRAX Approved in Japan for the Treatment of Genotype 1 Chronic Hepatitis C

Financial news for ENTA dated on 2015-05-26: AbbVie Announces Primary, Secondary Endpoints Met for Investigational Hep C Treatment in Japanese Patients Without Cirrhosis

Financial news for ENTA dated on 2015-05-26: Enanta Announces 95% SVR12 Results from AbbVie GIFT-1 Study in Non-cirrhotic, Japanese Patients with Genotype 1b Hep C Virus1

Financial news for ENTA dated on 2015-04-25: AbbVie Presents Preliminary Phase 3b Data with VIEKIRAX + EXVIERA in Chronic Hep C Patients with Renal Impairment at ILC 2015

Financial news for ENTA dated on 2015-04-24: FDA Accepts NDA, Grants Priority Review to AbbVie for OBV/PTV/r With RBV

Financial news for ENTA dated on 2015-04-15: Enanta Pharmaceuticals Announces AbbVie's Investigational Treatment Regimen for Genotype 1 Chronic Hepatitis C Granted Priority Review in Japan

Financial news for ENTA dated on 2015-04-06: Deutsche Bank Initiates Coverage on Enanta Pharmaceuticals at Buy, Announces \$42.00 PT

Financial news for ENTA dated on 2015-03-04: Barclays Initiates Coverage on Enanta Pharmaceuticals at Equal-weight, Announces \$35.00 PT

Financial news for ENTA dated on 2015-02-12: AbbVie Submits NDA in Japan for its Investigational, All-Oral, Treatment for Chronic Hepatitis C

Financial news for ENTA dated on 2015-01-16: EC Grants Marketing Authorizations for AbbVie's VIEKIRAX + EXVIERA for Treatment of Chronic Hepatitis C

Financial news for ENTA dated on 2014-12-22: Enanta Announces FDA Approval for AbbVie's VIEKIRA PAK

Financial news for ENTA dated on 2014-11-24: Enanta Pharma Reports Q3 EPS of \$(0.27) vs \$(0.33) Est; Revenue of \$2.60M vs \$3.81M Est

Financial news for ENTA dated on 2014-10-21: FBR Capital Maintains Outperform on Enanta Pharma, Lowers PT to \$50.00

Financial news for ENTA dated on 2014-08-11: Enanta Pharma Reports Q3 EPS of \$2.61 vs \$1.67 Est; Revenue of \$42.10M vs \$40.83M Est

Financial news for ENTA dated on 2014-08-07: Enanta Pharmaceuticals Announces Novartis Advanced EDP-239 into Combination Studies with Alisporivir

Financial news for ENTA dated on 2014-07-07: JMP Securities Downgrades Enanta Pharma to Market Perform, Removes \$50.00 PT

Financial news for ENTA dated on 2014-06-24: Baird Downgrades Enanta Pharma to Neutral, Maintains \$41.00 PT

Financial news for ENTA dated on 2014-06-17: Macquarie Initiates Coverage on Enanta Pharma at Outperform, Announces \$18.00 PT

Financial news for ENTA dated on 2014-04-11: AbbVie to Present Detailed Phase III Results from SAPPHERE-I and SAPPHERE-II Studies in Chronic Hepatitis C Patients at ILC 2014

Financial news for ENTA dated on 2014-03-24: AbbVie to Present Detailed Results from Phase III Studies in Patients with Chronic Hepatitis C at ILC

Financial news for ENTA dated on 2014-03-24: Enanta Pharmaceuticals Announces Eight Studies Have Been Accepted for Presentation at ILC

Financial news for ENTA dated on 2014-02-13: Enanta Pharma Reports Q1 EPS of \$(0.30) vs \$(0.15) Est; Revenue of \$893.0K vs \$1.41M Est

Financial news for ENTA dated on 2013-11-03: Enanta Pharmaceuticals Announces Additional Data from AbbVie's M13-393 Study to be Presented at Liver Meeting

Financial news for ENTA dated on 2013-08-12: Enanta Pharma Reports Q3 EPS of \$(0.23) vs \$(0.34) Est

Financial news for ENTA dated on 2013-05-08: Enanta Pharma Reports Q2 EPS of \$(2.28) Which May Not Compare \$(0.34) Est

Financial news for ENTA dated on 2013-04-23: Enanta Announces Data from Phase 2b Study for ABT-450 for Hepatitis C

Financial news for ENTA dated on 2013-04-15: Credit Suisse Initiates Coverage on Enanta Pharma at Outperform, Announces \$29.00 PT

Financial news for ENTA dated on 2013-04-15: Leerink Swann Initiates Coverage on Enanta Pharma at Outperform

Financial news for ENTA dated on 2013-04-15: JMP Securities Initiates Coverage on Enanta Pharma at Market Outperform, Announces \$25.00 PT

Financial news for ENTA dated on 2013-04-15: JP Morgan Initiates Coverage on Enanta Pharma at Overweight, Announces \$25.00 PT

Financial news for ENTA dated on 2012-11-06: Enanta Pharma Files \$69M IPO, Will Trade on NASDAQ